Molecular Characterization of Carbapenem-Resistant Enterobacteriaceae in the USA, 2011–2015

Uzma Ansari, Centers for Disease Control and Prevention
Adrian Lawsin, Centers for Disease Control and Prevention
Davina Campbell, Centers for Disease Control and Prevention
Valerie Albrecht, Centers for Disease Control and Prevention
Gillian McAllister, Centers for Disease Control and Prevention
Sandra Bulens, Centers for Disease Control and Prevention
Maroya Spalding Walters, Centers for Disease Control and Prevention
Jesse Jacob, Emory University
Sarah Satola, Emory University
Lucy E Wilson, Maryland Department of Health and Mental Hygiene

Only first 10 authors above; see publication for full author list.

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: Oxford University Press (OUP) | 2017-10-04, Pages S179-S179
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofx163.328
Permanent URL: https://pid.emory.edu/ark:/25593/s6g6g

Final published version: http://dx.doi.org/10.1093/ofid/ofx163.328

Copyright information:
© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed June 17, 2018 11:33 PM EDT
measures to minimize the economic impact of these infections and improve clinical outcomes in hospitalized patients.

Table 1. LOS and Hospital Cost

<table>
<thead>
<tr>
<th>Metric</th>
<th>Mean (SD)</th>
<th>Median</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital LOS (days)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDR PA</td>
<td>21 (19)</td>
<td>14</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Non-MDR PA</td>
<td>17 (16)</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>CR PA</td>
<td>22 (20)</td>
<td>14</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Non-CR PA</td>
<td>17 (16)</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Hospital Costs (US $)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDR PA</td>
<td>91,178 (106,913)</td>
<td>51,845</td>
<td>0.0007</td>
</tr>
<tr>
<td>Non-MDR PA</td>
<td>69,118 (74,389)</td>
<td>39,973</td>
<td></td>
</tr>
<tr>
<td>CR PA</td>
<td>85,819 (101,457)</td>
<td>49,135</td>
<td>0.0007</td>
</tr>
<tr>
<td>Non-CR PA</td>
<td>61,434 (62,717)</td>
<td>39,632</td>
<td></td>
</tr>
</tbody>
</table>


Janvas L. Kersin, VMH, MD1,2, Angela Tang, MPH1; Stephanie Black, MD, MS2; Massimo Pacilli, MS MPH1; Michael Y. Lin, MD, MPH2; William E. Trck, MD1,3 and Sarah K. Kemble, MD3; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, 1Chicago Department of Public Health, Chicago, Illinois, 2Illinois Department of Public Health, Chicago, Illinois, 3Eck Institute, Rush University Medical Center, Chicago, Illinois, 4Cook County Health and Hospitals System, Chicago, Illinois

**Session:** 57. HAI: Surveillance + Reporting

**Background.** Carbapenem-resistant Enterobacteriaceae (CRE) are a group of multidrug-resistant bacteria that cause >9,000 infections annually; ~50% of CRE bloodstream infections are fatal. The use of contact precautions (CP) for CRE patients can prevent transmission. To improve CRE surveillance and interfacility communication about positive patients, Illinois implemented the extensively drug-resistant organism (XDRO) registry in 2013. Healthcare facilities must report a patient's first positive CRE culture per stay up to 7 days from culture confirmation. Facilities can query the registry at patient discharge to identify CRE status and implement transmission precautions. We assessed facility timeliness of reporting and querying frequency and registry usefulness in identifying patients who should be on CP.

**Methods.** We analyzed Chicago XDRO data for November 2013–October 2016. Variables were facility type (hospital, long-term acute care hospital [LTACH], and skilled nursing facility [SNF]), culture date, and report date. Timeliness was time from culture collection to reporting. Nine facilities (2 hospitals, 4 LTACHs and 3 SNFs) completed a survey on querying frequency, all but 1 LTACH provided single day censused contact and precaution lists. We compared these with the XDRO registry to identify CRE patients for whom querying would have initiated CP use. We assessed facility timeliness of reporting and querying frequency and registry usefulness in identifying patients who should be on CP.

**Results.** Chicago facilities reported 2,469 CRE cases. Median timeliness varied by facility type: hospitals: 8 days; SNFs: 10 days; and LTACH: 55 days. Of patients on CP for >7 days, 22% had not reported to the registry. 11 IPDs, 152 LTACHs, and 203 SNFs were in LTACHs. Reported querying frequency was daily for 1 hospital and rarely for other facilities. Overall, 91 patients at 8 facilities were in the registry; of these, 0.1% (0%) hospital, 0.3% (27/11) LTACH, and 0.4% (44) SNFs patients were not on CP.

**Conclusion.** Timeliness of reporting CRE patients to the XDRO registry varied by facility type and exceeded the 7-day timeframe. Routine registry querying can identify CRE patients who should be on CP. Querying was uncommon in surveyed facilities, identifying an opportunity to improve transmission precautions among CRE patients, particularly in SNFs. We recommend facilities report cases in a timely manner and query the registry at patient admission.

**Disclosures.** M. Y. Lin, CareFusion Foundation: Grant Investigator, Research grant.

470. Antibiotic Resistance Increases with Local Temperature

Derek MacFaddlen, MD1; Sarah McCough, MSc2; David Fosman, MD3; Mircofilli Sanfilirna, PhD4 and John Brownstein, PhD5; Infectious Diseases, University of Toronto, Toronto, ON, Canada, 1Harvard School of Public Health, Boston, Massachusetts, 2University of Toronto, Toronto, ON, Canada, 3Harvard Medical School, Boston, Massachusetts

**Session:** 57. HAI: Surveillance + Reporting

**Background.** Antibiotic resistance is considered as one of our greatest emerging public health threats. Current understanding of the factors governing spread of antibiotic-resistant organisms and mechanisms among populations is limited.

**Methods.** We explored the roles of local temperature, population density, and additional factors on the distribution of antibiotic resistance across the United States, using a database of regional antibiotic resistance that incorporates over 1.6 million bacterial isolates from over 1,465 locations from human clinical isolates over the years 2013–2015.

**Results.** We identified that increasing local temperature as well as population density were associated with increasing antibiotic resistance in common pathogens. An increase in temperature of 10°C was associated with increases in antibiotic resistance of 4.2%, 2.2%, and 3.6% for the common pathogens Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus. The effect of temperature on antibiotic resistance was robust across almost all classes of antibiotics and pathogens and strengthened over time.

**Conclusion.** These findings suggest that current forecasts of the burden of antibiotic resistance could be significant underestimates in the face of a growing population and warming planet.

Figure 1. Antibiotic resistance increases with increasing temperature. (A) A heatmap of mean normalized antibiotic resistance for E. coli for all antibiotics across the USA. (B) A heatmap of 30-year average minimum temperature (°C) across the USA.

**Disclosures.** All authors: No reported disclosures.


Uzma Ansari, MS1, Siddiqui, MS2; Adyan Lawan, MS1; Davina Campbell, MPH1; Valerie Albrecht, MPH1; GilFann McAllister, BS1; Sand accelerator, MPH1; Maroya Spalding Walters, PhD2; ScM1, Jesse T. Jacob, MD3,4; W. Satoda, PhD3; Satoda, PhD3; ScM1; Ruth Lyndfield, MD4, FIDSA5; Paula M Snippes Vagnone, MD5,6; Sarah J. Janelle, MPH, CIC5; Karen Xavier, MT5,6; Ghiniwa Dumyati, MD1, FSHEA6; Dwight Hardy, PhD6; Erin C. Phipps, DVM, MPH1; Karissa Culbath, PhD1,6; Zutars Beldavs, MS1; Karim Morsy, MS1; Marion A. Kainer, MBBS, MPH, FSHEA1,6; Sheri Roberts, MT5,6; Alexander Kallen, MD, MPH1, J. Kamile Rasheed, PhD1, and Maria S. Karlsson, PhD1; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, 1Georgia Emerging Infections Program, Decatur, Georgia, 2Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, 3Georgia Emerging Infections Program, Atlanta, Georgia, 4Maryland Department of Health and Mental Hygiene, Baltimore, MD, 5Minnesota Department of Health, St. Paul, Minnesota, 6Colorado Department of Public Health and Environment, Denver, Colorado, 7New York Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York, 8New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, New Mexico, 9Tracore Reference Laboratories, Albuquerque, New Mexico, 10University of New Mexico School of Medicine, Albuquerque, New Mexico, 11Oregon Health Authority, Portland, OR, 12Tennessee Department of Public Health, Nashville, TN

**Session:** 57. HAI: Surveillance + Reporting

**Background.** Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as an important cause of healthcare-associated infections. We characterized the molecular epidemiology of CRE in isolates collected through the Emerging Infections Program (EIP) at the Centers for Disease Control and Prevention (CDC).

**Methods.** From 2011–2013, 8 U.S. EIP sites (CO, GA, MA, MN, NY, TN and OR) collected CRE (Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae complex, Klebsiella pneumoniae, and Klebsiella oxytoca) isolated from a normally sterile site or urine. Isolates were sent to CDC for reference antimicrobial susceptibility testing and real-time PCR detection of carbapenemase genes (bla_kpc, bla_mop, and bla_vbnc). Phenotypically confirmed CRE were analyzed by whole genome sequencing (WGS) using an Illumina MiSeq benchtop sequencer.

**Results.** Among 639 Enterobacteriaceae evaluated, 414 (65%) were phenotypically confirmed as CRE using CDC's current surveillance definition (resistant to ertapenem, imipenem, doripenem, or meropenem). Among isolates confirmed as CRE, 303 (73%) were carbapenemase-producers (CP-CRE). The majority of CP-CRE originated from GA (39%), MD (35%) and MN (11%); most non-CPCREs originated from MN (27%), CO (25%) and OR (17%). K. pneumoniae was the predominant carbapenemase-producing species (78%) followed by E. cloacae complex spp (12%), E. coli (7%), E. aerogenes (0.9%) and K. oxytoca (0.6%). The most common carbapenemase genes detected were bla_kpc (76%) and bla_mop (19%); bla_carb and bla_vbnc-like genes were detected in 1.6% and 0.3% of isolates, respectively. For carbapenemase-producing K. pneumoniae, Enterobacter spp, and E. coli, the predominant sequence types (ST) were ST258 (65%), ST171 (35%) and ST131 (29%), respectively.

**Conclusion.** The distribution of CP and non-CP CRE varied across the catchment area. Among CP-CRE, KPC-producing K. pneumoniae predominated; other carbapenemases were rarely identified in the locations under surveillance. Strain types known to have increased epidemic potential (ST258 and ST131) were common among carbapenemase-producing K. pneumoniae and E. coli isolates, respectively.

**Disclosures.** All authors: No reported disclosures.

472. Instituting Public Health Laboratory Surveillance for Methicillin-resistant Staphylococcus aureus (MRSA), Extended-Spectrum β Lactamase producing Enterobacteriaceae (ESBL) and Carbapenem-resistant Enterobacteriaceae (CRE) in a Large Metropolitan County

Poster Abstracts • OFID 2017:4 (Suppl 1) • S179

Downloaded from https://academic.oup.com/ofid/article-abstract/4/suppl_1/S179/4294266 by Pitts Theology Library, Emory University user on 27 November 2017